CLDN6-CAR-NK cell therapy / Second Affiliated Hospital of Guangzhou Medical University - LARVOL DELTA

NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. (PubMed, Int J Biol Sci) - "More importantly, CAR-NK cells combined with immune checkpoint inhibitors, anti-PD-L1, could synergistically enhance the antitumor efficacy of CLDN6-targeted CAR-NK cells. These results indicate that CLDN6-CAR NK cells possess strong antitumor activity and represent a promising immunotherapeutic modality for ovarian cancer."

IO biomarker • Journal • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • CLDN6 • NKG2D

CLDN6-CAR-NK Cell Therapy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Second Affiliated Hospital of Guangzhou Medical University

New P1/2 trial • Endometrial Cancer • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN6